Cerniglia M - Search Results

1

Khan AA, Khan IM, Nguyen PP, Lo E, Chahadeh H, Cerniglia M, Noriega JA. Khan AA, et al. Among authors: cerniglia m. Clin Podiatr Med Surg. 2020 Oct;37(4):821-835. doi: 10.1016/j.cpm.2020.07.007. Clin Podiatr Med Surg. 2020. PMID: 32919607 Review.

2

Combination of Evans calcaneal osteotomy and STA-Peg arthroreisis for correction of the severe pes valgo planus deformity.

Bruyn JM, Cerniglia MW, Chaney DM. Bruyn JM, et al. Among authors: cerniglia mw. J Foot Ankle Surg. 1999 Sep-Oct;38(5):339-46. doi: 10.1016/s1067-2516(99)80005-2. J Foot Ankle Surg. 1999. PMID: 10553547

3

Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC.

Cerniglia M, Klepadlo M, Sheneman D, Kim SS. Cerniglia M, et al. BMJ Case Rep. 2022 Aug 12;15(8):e250009. doi: 10.1136/bcr-2022-250009. BMJ Case Rep. 2022. PMID: 35961684

4

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes.

Wells L, Cerniglia M, Hall S, Jost AC, Britt G. Wells L, et al. Among authors: cerniglia m. J Immunother Precis Oncol. 2022 May 19;5(2):37-42. doi: 10.36401/JIPO-22-3. eCollection 2022 May. J Immunother Precis Oncol. 2022. PMID: 35664089 Free PMC article.

5

Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers.

Cerniglia M, Xiu J, Grothey A, Pishvaian MJ, Baca Y, Hwang JJ, Marshall JL, VanderWalde AM, Shields AF, Lenz HJ, Korn WM, Salem M, Philip PA, Goldberg RM, Zeng J, Kim SS. Cerniglia M, et al. Mol Cancer Ther. 2022 Jan;21(1):227-236. doi: 10.1158/1535-7163.MCT-20-0879. Epub 2021 Nov 1. Mol Cancer Ther. 2022. PMID: 34725190 Free PMC article.

6

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Wong DJ, et al. Among authors: cerniglia m. Mol Cancer. 2015 Jul 2;14:128. doi: 10.1186/s12943-015-0393-2. Mol Cancer. 2015. PMID: 26134498 Free PMC article. No abstract available.

7

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.

Atefi M, Titz B, Avramis E, Ng C, Wong DJ, Lassen A, Cerniglia M, Escuin-Ordinas H, Foulad D, Comin-Anduix B, Graeber TG, Ribas A. Atefi M, et al. Among authors: cerniglia m. Mol Cancer. 2015 Feb 3;14(1):27. doi: 10.1186/s12943-015-0293-5. Mol Cancer. 2015. PMID: 25645078 Free PMC article.

8

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.

Wong DJ, Robert L, Atefi MS, Lassen A, Avarappatt G, Cerniglia M, Avramis E, Tsoi J, Foulad D, Graeber TG, Comin-Anduix B, Samatar A, Lo RS, Ribas A. Wong DJ, et al. Among authors: cerniglia m. Mol Cancer. 2014 Aug 20;13:194. doi: 10.1186/1476-4598-13-194. Mol Cancer. 2014. PMID: 25142146 Free PMC article.

9

Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, Comin-Anduix B, Ribas A. Atefi M, et al. Among authors: cerniglia m. Clin Cancer Res. 2014 Jul 1;20(13):3446-57. doi: 10.1158/1078-0432.CCR-13-2797. Epub 2014 May 8. Clin Cancer Res. 2014. PMID: 24812408 Free PMC article.

10

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.

Lassen A, Atefi M, Robert L, Wong DJ, Cerniglia M, Comin-Anduix B, Ribas A. Lassen A, et al. Among authors: cerniglia m. Mol Cancer. 2014 Apr 16;13:83. doi: 10.1186/1476-4598-13-83. Mol Cancer. 2014. PMID: 24735930 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

17 results

Search Page